Gonadotropin-releasing hormone (GnRH) therapy improves cognitive function in Down syndrome (DS) mouse models and male patients with DS, according to a new study.
The findings reveal a previously underappreciated role of GnRH – a hormone commonly associated with fertility and reproduction – in olfaction and cognition and offer a promising pathway toward therapies that could improve the cognitive deficits in DS.
Down syndrome, also known as trisomy 21, is the most common genetic cause of intellectual disability and occurs in one in 30 pregnancies for women aged 45 or more and is caused by having 3 copies of chromosome 21 instead of the usual 2.
Among the various clinical manifestations associated with the condition, many adult DS patients experience symptoms like those of early-onset Alzheimer’s disease, as well as a gradual loss of olfaction. Additionally, men with DS may also display deficits in sexual maturation. Currently, however, there are no viable treatment options for the cognitive and olfactory deficits associated with DS.
Recent research has suggested that olfaction loss and male infertility is also a characteristic of GnRH deficiency, and that GnRH may play a role in higher brain functions, such as cognition. Whether GnRH plays a role in DS pathology isn’t fully understood.
In a mouse model of DS, the researchers discovered that strands of microRNA regulating the production of GnRH – which are found on chromosome 21 – were dysfunctional, resulting in abnormalities in the neurons that secrete the hormone.
The authors show that epigenetic, cellular, chemogenic, and pharmacological interventions that restore GnRH functions reversed olfactory and cognitive defects in DS mice as well as in a mouse model of Alzheimer’s disease.
Building on these findings, the authors conducted a pilot clinical trial to assess the effects of GnRH therapy on cognition in seven adult male DS patients. While the treatment did not affect olfaction, cognitive performance increased in all but one of the participants.
https://www.science.org/doi/10.1126/science.abq4515
GnRH therapy improves cognition in patients with Down syndrome
- 687 views
- Added
Latest News
A change in brain function…
By newseditor
Posted 06 Feb
Structures of LRP2 reveal a…
By newseditor
Posted 06 Feb
The structure of a function…
By newseditor
Posted 05 Feb
How tumor suppressor loss e…
By newseditor
Posted 05 Feb
Regulating feature-specific…
By newseditor
Posted 05 Feb
Other Top Stories
Silent synapses are abundant in the adult brain
Read more
The brain's microglia activation slows down Alzheimer's disease
Read more
Social trauma activates brain circuit to block social reward and pr…
Read more
An alternative splicing modulator decreases mutant HTT in Huntingto…
Read more
Changing the intrinsic behavior of neurons
Read more
Protocols
High-yield vesicle-packaged…
By newseditor
Posted 05 Feb
Machine learning prediction…
By newseditor
Posted 09 Jan
Differentiating PC12 cells…
By newseditor
Posted 09 Jan
Ultrasensitive sensors reve…
By newseditor
Posted 05 Jan
In vitro-derived medium spi…
By newseditor
Posted 04 Jan
Publications
Disinhibition of the orbito…
By newseditor
Posted 06 Feb
Renal control of life-threa…
By newseditor
Posted 06 Feb
Synaptotagmin-1 is a Ca2+ s…
By newseditor
Posted 06 Feb
Cardiometabolic health impr…
By newseditor
Posted 06 Feb
Regulation of ribosomal RNA…
By newseditor
Posted 06 Feb
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 10 Mar
ASCO-2020-GYNECOLOGIC CANCER
By newseditor
Posted 10 Mar